monovalent H1N1 influenza virus subunit vaccine

The monovalent H1N1 influenza virus subunit vaccine is an inactivated, subunit vaccine developed by Novartis Vaccines and Diagnostics to address the 2009 H1N1 influenza pandemic. It is composed of the surface antigen hemagglutinin (HA) from the A/California/7/2009 (H1N1)v-like virus strain. The vaccine was produced in two primary forms: an egg-derived version marketed as **Focetria** and a cell-culture-derived version (using MDCK cells) marketed as **Celtura**. Both formulations are typically adjuvanted with **MF59**, a squalene-based oil-in-water emulsion designed to boost the immune response, particularly in vulnerable populations such as children and the elderly. The vaccine works by inducing the production of hemagglutination-inhibiting antibodies that neutralize the virus. Focetria received approval from the European Medicines Agency (EMA) and was used extensively in Europe and Latin America, while Celtura was approved in several countries including Germany and Switzerland.

Brand names

FocetriaCeltura

Other names

monovalent H1N1 influenza virus subunit vaccineH1N1v vaccineH-1N1v vaccineH 1N1v vaccineA/H1N1 2009 pandemic influenza vaccineMF59-adjuvanted monovalent H1N1 vaccineMF-59-adjuvanted monovalent H1N1 vaccineMF 59-adjuvanted monovalent H1N1 vaccinepandemic influenza vaccine (H1N1) (surface antigen, inactivated, adjuvanted)